Five named tertiary centres and a private-hospital channel of four groups define the addressable GCC IgA nephropathy network, against a base of roughly 300 nephrologists and 5 to 10 recognised national KOLs.
GCC IgA nephropathy diagnosis and treatment concentrate at a small set of tertiary institutions: KFSH&RC, Saudi Arabia's largest glomerular-disease programme, Hamad Medical Corporation in Doha, AUH, King Fahd Hospital in Jeddah, and University Hospital Sharjah. Kidney biopsy, the confirmatory step IgAN diagnosis requires, is available only at these centres, structurally capping the addressable population to patients who reach specialist nephrology care. Of the roughly 300 nephrologists practicing across the GCC, only 30 to 50 carry glomerular-disease subspecialty interest, and the recognised national KOL list runs to just 5 to 10 individuals. Our KOL Universe gate (K1) starts by sizing this concentrated institutional base before scoring any single physician.
A second, faster-moving channel sits alongside the public tertiary centres: private hospital groups, American Hospital Dubai, Burjeel, Saudi German, and Mouwasat, that have begun prescribing budesonide (Tarpeyo) ahead of GCC-wide formulary listing and represent the fastest access channel for a newly registered agent. Neither Tarpeyo nor sparsentan (Filspari) is SFDA-registered as of 2024, so hospital-by-hospital access decisions, not a national formulary, currently determine which institution a manufacturer must engage first. Our Tier Classification gate (K2) scores public-tertiary and private-channel institutions separately, since their influence over prescribing runs through different committee structures, and no named individual enters the workbook without a verification tag checked against live institutional-affiliation records.
The GCC IgA nephropathy network: five named tertiary centres and a four-group private hospital channel
| Institution | Location | Channel |
|---|---|---|
| KFSH&RC | Riyadh, Saudi Arabia | Public tertiary; Saudi Arabia's largest glomerular-disease programme |
| Hamad Medical Corporation | Doha, Qatar | Public tertiary referral centre |
| AUH | UAE | Public tertiary referral centre |
| King Fahd Hospital | Jeddah, Saudi Arabia | Public tertiary referral centre |
| University Hospital Sharjah | Sharjah, UAE | Public tertiary referral centre |
| American Hospital Dubai, Burjeel, Saudi German, Mouwasat | UAE / Saudi Arabia | Private hospital channel; fastest current access route for a newly registered agent |
Sources: Saudi Society of Nephrology membership data; GCC nephrology congress programme 2023; SFDA drug registration database query; Gulf Nephrology Society formulary review 2023; NPHC exceptional access framework documentation.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The five named tertiary centres (KFSH&RC, Hamad Medical Corporation Doha, AUH, King Fahd Hospital Jeddah, University Hospital Sharjah)
- institutional concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology separating public and private-channel institutions
- American Hospital Dubai, Burjeel, Saudi German, and Mouwasat as the private-channel comparator set
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration across five named tertiary centres, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the public-tertiary versus private-hospital channel split before the rest of the workbook is built out
- Every GCC IgAN institutional stakeholder and KOL sized and sourced from institutional-affiliation and registration data
- The five named tertiary centres and the four-group private hospital channel as the sizing anchor
- Universe boundaries: recognised national KOL versus high-volume prescriber
- Scientific-influence scoring across public-tertiary and private-channel institutions
- What separates a national KOL from a high-volume community prescriber
- Influence inputs: institutional role, glomerular-disease subspecialty status, private-channel prescribing activity
- Cross-checked against independent institutional and registration data
- Readiness scoring and channel recommendations per institution
- Sequencing implications given the empty GCC formulary and hospital-by-hospital access route
- Territory-to-institution coverage map across Saudi Arabia, Qatar, and the UAE
- Where current MSL deployment has gaps
- Multi-market reach for institutions and KOLs active beyond a single GCC state
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live institutional-affiliation and registration data, not secondary summaries. No KOL name or institution ships without a verification tag.
GCC IgA nephropathy KOL sources: Saudi Society of Nephrology membership data, the GCC nephrology congress programme 2023, the SFDA drug registration database, and the Gulf Nephrology Society formulary review 2023.
- Named tertiary institution list verified against Saudi Society of Nephrology membership data and the GCC nephrology congress programme 2023
- Nephrologist and subspecialty counts verified against Saudi Society of Nephrology membership data
- SFDA registration status for budesonide and sparsentan verified against the SFDA drug registration database query
- Every KOL and institutional entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC IgA nephropathy specialists ahead of SFDA registration. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.